These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3608508)

  • 1. Optimal restricted two-stage designs.
    Case LD; Morgan TM; Davis CE
    Control Clin Trials; 1987 Jun; 8(2):146-56. PubMed ID: 3608508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On efficient two-stage adaptive designs for clinical trials with sample size adjustment.
    Liu Q; Li G; Anderson KM; Lim P
    J Biopharm Stat; 2012; 22(4):617-40. PubMed ID: 22651105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal two-stage designs for clinical trials with binary response.
    Thall PF; Simon R; Ellenberg SS; Shrager R
    Stat Med; 1988 May; 7(5):571-9. PubMed ID: 3387716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal adaptive two-stage designs for phase II cancer clinical trials.
    Englert S; Kieser M
    Biom J; 2013 Nov; 55(6):955-68. PubMed ID: 23868324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Optimal conditional error functions for the control of conditional power.
    Brannath W; Bauer P
    Biometrics; 2004 Sep; 60(3):715-23. PubMed ID: 15339294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Group sequential designs for three-arm 'gold standard' non-inferiority trials with fixed margin.
    Schlömer P; Brannath W
    Stat Med; 2013 Dec; 32(28):4875-89. PubMed ID: 23970488
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal adaptive two-stage designs for early phase II clinical trials.
    Shan G; Wilding GE; Hutson AD; Gerstenberger S
    Stat Med; 2016 Apr; 35(8):1257-66. PubMed ID: 26526165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficient group sequential designs when there are several effect sizes under consideration.
    Jennison C; Turnbull BW
    Stat Med; 2006 Mar; 25(6):917-32. PubMed ID: 16220524
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimal spending functions for asymmetric group sequential designs.
    Anderson KM
    Biom J; 2007 Jun; 49(3):337-45. PubMed ID: 17623339
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interim analysis and sample size reassessment.
    Posch M; Bauer P
    Biometrics; 2000 Dec; 56(4):1170-6. PubMed ID: 11129475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Including sampling and phenotyping costs into the optimization of two stage designs for genomewide association studies.
    Müller HH; Pahl R; Schäfer H
    Genet Epidemiol; 2007 Dec; 31(8):844-52. PubMed ID: 17549751
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adaptive two-stage designs in phase II clinical trials.
    Banerjee A; Tsiatis AA
    Stat Med; 2006 Oct; 25(19):3382-95. PubMed ID: 16479547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal designs for clinical trials with dichotomous responses.
    Berry DA; Pearson LM
    Stat Med; 1985; 4(4):497-508. PubMed ID: 4089351
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials.
    Mander AP; Thompson SG
    Contemp Clin Trials; 2010 Nov; 31(6):572-8. PubMed ID: 20678585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimizing trial design in pharmacogenetics research: comparing a fixed parallel group, group sequential, and adaptive selection design on sample size requirements.
    Boessen R; van der Baan F; Groenwold R; Egberts A; Klungel O; Grobbee D; Knol M; Roes K
    Pharm Stat; 2013; 12(6):366-74. PubMed ID: 24214896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An optimal design for screening trials.
    Wang YG; Leung DH
    Biometrics; 1998 Mar; 54(1):243-50. PubMed ID: 9544519
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sample sizes for group sequential cohort and case-control study designs.
    Pasternack BS; Shore RE
    Am J Epidemiol; 1981 Feb; 113(2):182-91. PubMed ID: 7468575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adaptive Designs with Discrete Test Statistics and Consideration of Overrunning.
    Schmidt R; Burkhardt B; Faldum A
    Methods Inf Med; 2015; 54(5):434-46. PubMed ID: 26429500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reasonable two-stage adaptive designs for single-arm phase II clinical trials.
    Kashiwabara K; Matsuyama Y
    Pharm Stat; 2018 Nov; 17(6):770-780. PubMed ID: 30168250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of multistage testing times and critical values in clinical trials.
    Brittain EH; Bailey KR
    Biometrics; 1993 Sep; 49(3):763-72. PubMed ID: 8241372
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.